To include your compound in the COVID-19 Resource Center, submit it here.

EC approves Merck KGaA's cladribine tablets for MS

The European Commission approved Mavenclad cladribine tablets from Merck KGaA (Xetra:MRK) to treat highly

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE